Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 11/20 | 0.62 |
| ▸ | HTR2C | P28335 | 4/20 | 0.43 |
| ▸ | HTR2A | P28223 | 3/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.43 |
| ▸ | HTR2B | P41595 | 3/20 | 0.43 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.41 |
| ▸ | HTR1A | P08908 | 2/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 6/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5060507 | 0.85 | SETD7 (0.59) | HRH1HTR2CHTR2AADRA1AHTR2B | |
| SCHEMBL6988125 | 0.83 | HRH1 (0.58) | HRH1HTR2CHTR2AADRA1AHTR2B | |
| SCHEMBL6987948 | 0.81 | HRH1 (0.47) | HRH1HTR2CHTR2AADRA1AHTR2B | |
| SCHEMBL25779928 | 0.80 | KDM4E (0.44) | HRH1HTR2CHTR2AADRA1AHTR2B | |
| SCHEMBL30561615 | 0.80 | KDM4E (0.44) | HRH1HTR2CHTR2AADRA1AHTR2B | |
| SCHEMBL6995295 | 0.79 | HRH1 (0.43) | HRH1HTR2CHTR2AADRA1AHTR2B | |
| SCHEMBL9167967 | 0.79 | PTAFR (0.64) | HRH1PTAFRFNTAFNTB | |
| SCHEMBL6991281 | 0.79 | HRH1 (0.43) | HRH1HTR2CHTR2AADRA1AHTR2B | |
| SCHEMBL6989791 | 0.78 | HRH1 (0.40) | HRH1HTR2CHTR2AADRA1AHTR2B | |
| SCHEMBL6984394 | 0.78 | HRH1 (0.42) | HRH1HTR2CHTR2AADRA1AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0518435-A1 | Imidazo[2,1-b][3]benzazepine derivatives, compositions and method of use | JANSSEN PHARMACEUTICA N.V. (BE) | 1992-12-16 | — | — | EP | claimed |
| US-9650385-B2 | Polymorphic form of alcaftadine, composition and process | ENALTEC LABS PVT. LTD. (IN) | 2017-05-16 | — | — | US | disclosed |
| US-9650385-B2 | Polymorphic form of alcaftadine, composition and process | ENALTEC LABS PVT. LTD. (IN) | 2017-05-16 | — | — | US | disclosed |
| US-9580436-B2 | Process of preparing alcaftadine | ENALTEC LABS PRIVATE LIMITED (IN) | 2017-02-28 | — | — | US | disclosed |
| US-9580436-B2 | Process of preparing alcaftadine | ENALTEC LABS PRIVATE LIMITED (IN) | 2017-02-28 | — | — | US | disclosed |
| US-20160362413-A1 | POLYMORPHIC FORM OF ALCAFTADINE, COMPOSITION AND PROCESS | ENALTEC LABS PVT. LTD. (IN) | 2016-12-15 | — | — | US | disclosed |
| US-20160362413-A1 | POLYMORPHIC FORM OF ALCAFTADINE, COMPOSITION AND PROCESS | ENALTEC LABS PVT. LTD. (IN) | 2016-12-15 | — | — | US | disclosed |
| US-9409913-B2 | Polymorphic forms of alcaftadine | ENALTEC LABS PRIVATE LIMITED (IN) | 2016-08-09 | — | — | US | disclosed |
| US-9409913-B2 | Polymorphic forms of alcaftadine | ENALTEC LABS PRIVATE LIMITED (IN) | 2016-08-09 | — | — | US | disclosed |
| US-20160083389-A1 | PROCESS OF PREPARING ALCAFTADINE | ENALTEC LABS PVT. LTD. (IN) | 2016-03-24 | — | — | US | disclosed |
| EP-0552292-B1 | SUBSTITUTED IMIDAZOBENZAZEPINES AND IMIDAZOPYRIDOAZEPINES | SCHERING CORP (US) | 1995-06-21 | — | — | EP | disclosed |
| US-5393753-A | Antiallergens, antiinflammatory agents | SCHERING CORPORATION (US) | 1995-02-28 | — | — | US | disclosed |
| EP-0588858-A1 | IMIDAZO 2,1-b] 3]BENZAZEPINE DERIVATIVES, COMPOSITIONS AND METHOD OF USE | JANSSEN PHARMACEUTICA N.V. (BE) | 1994-03-30 | — | — | EP | disclosed |
| EP-0588858-A1 | IMIDAZO 2,1-b] 3]BENZAZEPINE DERIVATIVES, COMPOSITIONS AND METHOD OF USE | JANSSEN PHARMACEUTICA N.V. (BE) | 1994-03-30 | — | — | EP | disclosed |
| EP-0552292-A1 | SUBSTITUTED IMIDAZOBENZAZEPINES AND IMIDAZOPYRIDOAZEPINES. | SCHERING CORP (US) | 1993-07-28 | — | — | EP | disclosed |
| WO-1992022551-A1 | IMIDAZO[2,1-b][3]BENZAZEPINE DERIVATIVES, COMPOSITIONS AND METHOD OF USE | JANSSEN PHARMACEUTICA N.V. (BE) | 1992-12-23 | — | — | WO | disclosed |
| WO-1992022551-A1 | IMIDAZO[2,1-b][3]BENZAZEPINE DERIVATIVES, COMPOSITIONS AND METHOD OF USE | JANSSEN PHARMACEUTICA N.V. (BE) | 1992-12-23 | — | — | WO | disclosed |
| EP-0518435-A1 | Imidazo[2,1-b][3]benzazepine derivatives, compositions and method of use | JANSSEN PHARMACEUTICA N.V. (BE) | 1992-12-16 | — | — | EP | disclosed |
| EP-0518435-A1 | Imidazo[2,1-b][3]benzazepine derivatives, compositions and method of use | JANSSEN PHARMACEUTICA N.V. (BE) | 1992-12-16 | — | — | EP | disclosed |
| WO-1992006981-A1 | SUBSTITUTED IMIDAZOBENZAZEPINES AND IMIDAZOPYRIDOAZEPINES | SCHERING CORPORATION (US) | 1992-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160083389-A1 | PROCESS OF PREPARING ALCAFTADINE | CYP4F2, CYP2F1, CYP1A2 | HRH1 1121/4885HTR2C 853/4885HTR2A 746/4885 |
| US-20160362413-A1 | POLYMORPHIC FORM OF ALCAFTADINE, COMPOSITION AND PROCESS | ADRA2C, UGT1A1, ADRA2A | HRH1 428/4885HTR2C 450/4885HTR2A 268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.